• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Immunity . Leveraging vaccination-induced protective antibodies to define conserved epitopes on influenza N2 neuraminidase

tetano

Editor, Senior Moderator
Immunity


. 2023 Nov 14;56(11):2621-2634.e6.
doi: 10.1016/j.immuni.2023.10.005. Leveraging vaccination-induced protective antibodies to define conserved epitopes on influenza N2 neuraminidase

Ruipeng Lei[SUP] 1 [/SUP], Wooseob Kim[SUP] 2 [/SUP], Huibin Lv[SUP] 3 [/SUP], Zongjun Mou[SUP] 4 [/SUP], Michael J Scherm[SUP] 5 [/SUP], Aaron J Schmitz[SUP] 6 [/SUP], Jackson S Turner[SUP] 6 [/SUP], Timothy J C Tan[SUP] 7 [/SUP], Yiquan Wang[SUP] 1 [/SUP], Wenhao O Ouyang[SUP] 1 [/SUP], Weiwen Liang[SUP] 8 [/SUP], Joel Rivera-Cardona[SUP] 9 [/SUP], Chuyun Teo[SUP] 1 [/SUP], Claire S Graham[SUP] 1 [/SUP], Christopher B Brooke[SUP] 9 [/SUP], Rachel M Presti[SUP] 10 [/SUP], Chris K P Mok[SUP] 11 [/SUP], Florian Krammer[SUP] 12 [/SUP], Xinghong Dai[SUP] 13 [/SUP], Ali H Ellebedy[SUP] 14 [/SUP], Nicholas C Wu[SUP] 15 [/SUP]



Affiliations
Abstract

There is growing appreciation for neuraminidase (NA) as an influenza vaccine target; however, its antigenicity remains poorly characterized. In this study, we isolated three broadly reactive N2 antibodies from the plasmablasts of a single vaccinee, including one that cross-reacts with NAs from seasonal H3N2 strains spanning five decades. Although these three antibodies have diverse germline usages, they recognize similar epitopes that are distant from the NA active site and instead involve the highly conserved underside of NA head domain. We also showed that all three antibodies confer prophylactic and therapeutic protection in vivo, due to both Fc effector functions and NA inhibition through steric hindrance. Additionally, the contribution of Fc effector functions to protection in vivo inversely correlates with viral growth inhibition activity in vitro. Overall, our findings advance the understanding of NA antibody response and provide important insights into the development of a broadly protective influenza vaccine.

Keywords: antibody; cross-reactive; cryo-EM; influenza virus; neuraminidase; protective; structures; vaccination.

 
Back
Top Bottom